Horne Benjamin D, Muhlestein Joseph B, Strobel Gunnar G, Carlquist John F, Bair Tami L, Anderson Jeffrey L
LDS Hospital, Salt Lake City, Utah 84143, USA.
Am Heart J. 2002 Sep;144(3):491-500. doi: 10.1067/mhj.2002.125010.
Restenosis after percutaneous coronary intervention (PCI) constitutes a serious complication in the treatment of cardiovascular disease, but known risk factors do not fully account for the observed restenosis risk. Preliminary studies of infection or inflammation in restenosis report varied results. We tested whether C-reactive protein (CRP) or pathogen burden (seropositivity to 0, 1, 2, or 3 pathogens, of Chlamydia pneumoniae [Cpn], cytomegalovirus [CMV], or Helicobacter pylori [Hpy]) predict clinical restenosis after percutaneous coronary intervention (PCI).
Blood samples were collected from 415 patients undergoing PCI, and levels of plasma CRP and antibodies to Cpn, CMV, and Hpy were measured. The patient's medical history, demographics, and procedural data were recorded. Patient end points were determined for as long as 6 months as a means of evaluating the incidence of clinical restenosis and major adverse cardiac events.
The average patient age was 62 years, and 80% of patients were male. Fifty-eight patients (14%) experienced clinical restenosis, whereas 17 patients (4%) died or had an acute myocardial infarction. After adjusting for 19 possible predictors, we found the pathogen burden (P-trend =.04, adjusted odds ratio [OR] 1.5 per number of pathogens) and minimum luminal diameter (P =.003, OR 1.8 per mm decrease) to be significant predictors of clinical restenosis. Male sex was a nonsignificant predictor of restenosis (P =.06, OR 2.2), but CRP was not significant after adjustment (P-trend =.10, OR 0.73 per tertile).
Pathogen burden was associated with clinical coronary restenosis, an association that deserves further exploration and evaluation. CRP, a marker of inflammation, was not associated with an increased risk of restenosis.
经皮冠状动脉介入治疗(PCI)后的再狭窄是心血管疾病治疗中的一种严重并发症,但已知的危险因素并不能完全解释所观察到的再狭窄风险。关于再狭窄中感染或炎症的初步研究报告结果不一。我们测试了C反应蛋白(CRP)或病原体负荷(对肺炎衣原体[Cpn]、巨细胞病毒[CMV]或幽门螺杆菌[Hpy]这0、1、2或3种病原体的血清阳性)是否能预测经皮冠状动脉介入治疗(PCI)后的临床再狭窄。
收集了415例行PCI患者的血样,检测血浆CRP水平以及针对Cpn、CMV和Hpy的抗体。记录患者的病史、人口统计学资料和手术数据。以长达6个月的患者终点来评估临床再狭窄和主要不良心脏事件的发生率。
患者平均年龄为62岁,80%为男性。58例患者(14%)发生临床再狭窄,而17例患者(4%)死亡或发生急性心肌梗死。在对19个可能的预测因素进行校正后,我们发现病原体负荷(P趋势=0.04,每增加一种病原体调整后的优势比[OR]为1.5)和最小管腔直径(P = 0.003,每减小1毫米OR为1.8)是临床再狭窄的显著预测因素。男性性别是再狭窄的非显著预测因素(P = 0.06,OR为2.2),但校正后CRP不显著(P趋势=0.10,每三分位数OR为0.73)。
病原体负荷与临床冠状动脉再狭窄相关,这种关联值得进一步探索和评估。炎症标志物CRP与再狭窄风险增加无关。